Targeted immunotherapy for HER2-low breast cancer with 17p loss.
Journal
Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086
Informations de publication
Date de publication:
10 02 2021
10 02 2021
Historique:
received:
08
05
2020
accepted:
13
01
2021
entrez:
11
2
2021
pubmed:
12
2
2021
medline:
13
7
2021
Statut:
ppublish
Résumé
The clinical challenge for treating HER2 (human epidermal growth factor receptor 2)-low breast cancer is the paucity of actionable drug targets. HER2-targeted therapy often has poor clinical efficacy for this disease due to the low level of HER2 protein on the cancer cell surface. We analyzed breast cancer genomics in the search for potential drug targets. Heterozygous loss of chromosome 17p is one of the most frequent genomic events in breast cancer, and 17p loss involves a massive deletion of genes including the tumor suppressor
Identifiants
pubmed: 33568521
pii: 13/580/eabc6894
doi: 10.1126/scitranslmed.abc6894
pmc: PMC8351376
mid: NIHMS1724166
pii:
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : R01 CA203737
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA211861
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA213535
Pays : United States
Informations de copyright
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Références
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
NPJ Breast Cancer. 2019 Oct 8;5:34
pubmed: 31602395
Annu Rev Immunol. 2013;31:51-72
pubmed: 23157435
Genome Res. 2009 Sep;19(9):1639-45
pubmed: 19541911
Toxicol Sci. 2006 May;91(1):140-9
pubmed: 16495352
Lancet Oncol. 2017 Jun;18(6):732-742
pubmed: 28526536
Nat Rev Clin Oncol. 2020 Dec;17(12):725-741
pubmed: 32760014
Nat Med. 2014 Nov;20(11):1301-9
pubmed: 25344738
Nat Med. 2007 Jan;13(1):54-61
pubmed: 17187072
J Toxicol Clin Toxicol. 2002;40(6):715-57
pubmed: 12475187
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Nat Clin Pract Oncol. 2009 Feb;6(2):93-104
pubmed: 19107109
Nat Rev Cancer. 2009 Oct;9(10):749-58
pubmed: 19776744
Lancet Oncol. 2016 Jun;17(6):e254-e262
pubmed: 27299281
J Immunol. 2003 Dec 1;171(11):5787-94
pubmed: 14634087
Nat Rev Clin Oncol. 2019 Jul;16(7):399-400
pubmed: 31053774
Nat Rev Drug Discov. 2017 May;16(5):315-337
pubmed: 28303026
J Clin Oncol. 2000 Sep 15;18(18):3230-9
pubmed: 10986055
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Cell Rep. 2016 Apr 12;15(2):274-87
pubmed: 27050509
J Natl Cancer Inst. 2012 Apr 18;104(8):622-34
pubmed: 22457476
Gut. 2000 Jun;46(6):842-8
pubmed: 10807898
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
Nat Commun. 2018 Oct 22;9(1):4394
pubmed: 30349055
Genome Res. 1997 Dec;7(12):1123-37
pubmed: 9414318
Arch Toxicol. 2020 Jun;94(6):2061-2078
pubmed: 32193566
Cell Death Differ. 2017 May;24(5):832-843
pubmed: 28234357
J Clin Oncol. 2020 Feb 10;38(5):444-453
pubmed: 31821109
Nat Nanotechnol. 2019 Apr;14(4):388-397
pubmed: 30804480
J Clin Oncol. 2020 Jun 10;38(17):1887-1896
pubmed: 32058843
Nature. 2016 Mar 24;531(7595):471-475
pubmed: 26982726
Nature. 2015 Apr 30;520(7549):697-701
pubmed: 25901683
Methods Mol Biol. 2018;1711:243-259
pubmed: 29344893
J Clin Oncol. 1990 Jan;8(1):103-12
pubmed: 1967301
J Clin Oncol. 2007 Jan 1;25(1):118-45
pubmed: 17159189
J Exp Med. 2005 Dec 19;202(12):1691-701
pubmed: 16365148
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Mol Cancer Ther. 2013 Sep;12(9):1816-28
pubmed: 23723124
Science. 2013 Feb 15;339(6121):823-6
pubmed: 23287722
Oncoimmunology. 2015 Jul 25;4(8):e988042
pubmed: 26405588
J Clin Oncol. 2017 Jul 1;35(19):2141-2148
pubmed: 28291390
Science. 2013 Feb 15;339(6121):819-23
pubmed: 23287718
Nat Rev Cancer. 2009 Oct;9(10):724-37
pubmed: 19776742
Nat Biotechnol. 2008 Aug;26(8):925-32
pubmed: 18641636
J Immunol Methods. 2008 Mar 20;332(1-2):41-52
pubmed: 18230399
N Engl J Med. 2005 Oct 20;353(16):1673-84
pubmed: 16236738
Proc Natl Acad Sci U S A. 1991 May 1;88(9):3847-51
pubmed: 1673792